Chengdu Tianshizhen Biotechnology Co., Ltd.

Primary objectives: Cohort 1: To evaluate the effect of TG103 injection on the pharmacokinetics (PK) of valsartan capsules and warfarin sodium tablets in healthy Chinese subjects. Cohort 2: To evaluate the effect of TG103 injection on the PK of atorvastatin calcium tablets and digoxin tablets in healthy Chinese subjects. Secondary objectives: Cohort 1: To evaluate the PK characteristics and immunogenicity of TG103 injection after multiple administration in healthy Chinese subjects; to evaluate the effect of TG103 injection on the pharmacodynamics (PD) of warfarin sodium tablets; the safety and tolerability of TG103 injection, valsartan capsules and warfarin sodium tablets; to preliminarily explore the effect of TG103 injection on the QTc interval in healthy Chinese subjects. Cohort 2: To evaluate the PK characteristics and immunogenicity of TG103 injection after multiple administration in healthy Chinese subjects; to evaluate the safety and tolerability of TG103 injection, atorvastatin calcium tablets and digoxin tablets.

Primary purpose: To evaluate the pharmacokinetic characteristics of TG103 injection after a single subcutaneous injection in subjects with normal renal function and renal insufficiency. Secondary purpose: To evaluate the immunogenicity of TG103 injection after a single subcutaneous injection in subjects with normal renal function and renal insufficiency; To evaluate the safety and tolerability of TG103 injection after a single subcutaneous injection in subjects with normal renal function and renal insufficiency.

Main study objectives: In patients with type 2 diabetes who have poor glycemic control on metformin monotherapy, to evaluate the non-inferiority of TG103 injection 7.5mg and 15mg once weekly combined with metformin for 28 weeks in terms of HbA1c change from baseline to dulaglutide Secondary study objectives: 1. In patients with type 2 diabetes who have poor glycemic control on metformin monotherapy, to evaluate the non-inferiority of TG103 injection 7.5mg and 15mg once weekly combined with metformin for 52 weeks in terms of HbA1c change from baseline to dulaglutide; 2. In patients with type 2 diabetes who have poor glycemic control on metformin monotherapy, to evaluate the safety of TG103 injection combined with metformin; 3. To evaluate the pharmacokinetic (PK) characteristics of TG103 injection at different doses in subjects with type 2 diabetes; 4. To evaluate the immunogenicity of TG103 injection.